Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Lymphomatoid papulosis (LyP) is a benign condition, listed among primary cutaneous CD30+ lymphoproliferative disorders. Its typical picture consists of relapsing-remitting papular lesions and it can be encountered in the course of a hematologic disease, at times representing its first manifestation. Hypereosinophilic syndromes are a heterogeneous group of disorders characterized by persistent peripheral blood hypereosinophilia that may lead to life-threatening organ damage. Among eosinophilic disorders, the subtype identified as myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusions has aroused particular interest due to its excellent response to tyrosine kinase inhibitors, including imatinib. Here, we described the case of two 33-year-old men presenting with LyP and myeloid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement who achieved complete clinical and molecular remission of both conditions a few months after starting imatinib.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1346-8138.16836 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identifying Drug Combination Strategies for Fusion Positive Leukemia.
Precis Oncogenom
July 2025
Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN-TK) are a class of fusion protein-driven, poor prognosis leukemias. Leukemias harboring FGFR1 fusions have previously been referred to as 8p11.2 myeloproliferative syndrome (EMS) or stem cell leukemia/lymphoma (SCLL) and are currently referred to as Myeloid/lymphoid neoplasms with FGFR1 rearrangement based on the most recent WHO classification system.
View Article and Find Full Text PDFAtypical lymphoid proliferations associated with therapeutic intervention: a report of the 2024 EA4HP/SH lymphoma workshop.
Virchows Arch
August 2025
Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA.
The challenging boundaries between neoplastic and reactive lymphoproliferations were discussed during the 2024 European Association for Haematopathology/Society for Hematopathology workshop in Dubrovnik, Croatia. Session 3 focussed on the atypical lymphoid proliferations associated with therapeutic interventions. Forty-four cases were submitted representing a broad spectrum of lymphoproliferative disorders (LPDs) encountered in the settings of immunosuppressive and immunomodulatory therapies, various interventions for solid tumor treatment, drug reaction with eosinophilia and systemic symptoms (DRESS), CAR T-cell therapy for B-cell lymphomas, Bruton tyrosine kinase inhibitors (BTKI) for SLL/CLL treatment, ABL-kinase inhibitor dasatinib, and COVID-19 vaccination.
View Article and Find Full Text PDFCase Report: Pathologic complete response in a patient with simultaneous diagnoses of resectable NSCLC and myeloid neoplasm with PDGFRA rearrangement treated with concurrent neoadjuvant chemoimmunotherapy and imatinib: translating clinical trial data to real-world practice.
Front Oncol
July 2025
Department of Medicine, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, United States.
Neoadjuvant chemoimmunotherapy has become an established treatment approach in resectable non-small cell lung cancer (NSCLC). The utilization of neoadjuvant immune checkpoint blockade (ICB) and coordination of care in the real-world setting present important challenges, with limited data available for patients with multiple synchronous primary malignancies. This case describes a 57-year-old man with simultaneous diagnoses of resectable stage IIIA NSCLC and -rearranged myeloid neoplasm who received neoadjuvant chemotherapy and nivolumab in combination with imatinib prior to definitive resection.
View Article and Find Full Text PDFZMYM2-FLT3 Fusion Gene: Implications for Chromosomal Instability and Proliferation in Myeloid/Lymphoid Neoplasms.
FASEB J
August 2025
Department of Hematology, The First Hospital of China Medical University, Shenyang, China.
Myeloid/Lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN-TK) are rare hematological malignancies often characterized by eosinophilia and the presence of tyrosine kinase gene fusions. Among these, the ZMYM2::FLT3 (Z2F3) fusion gene is an uncommon genetic abnormality found in some MLN-TK patients. This study aimed to investigate the function and underlying mechanisms of the ZMYM2::FLT3 fusion gene identified in a young female patient.
View Article and Find Full Text PDFPrecision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs).
Best Pract Res Clin Haematol
June 2025
Division of Hematology Oncology, Department of Medicine, Massachusetts General Hospital, Boston, USA. Electronic address:
The utilization of immune checkpoint inhibitors has fundamentally changed both the treatment landscape for a multitude of malignancies as well as our understanding of cancer biology. Despite profound advancements, the utilization of these drugs is often limited by the development of immune-related adverse events (irAEs), characterized by off-target toxicity to healthy tissue secondary to treatment. Currently, irAEs are often treated with high-dose corticosteroids, with additional immunosuppressive agents added for severe or refractory irAEs.
View Article and Find Full Text PDF